269 related articles for article (PubMed ID: 35576960)
21. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
22. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S
Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
[TBL] [Abstract][Full Text] [Related]
24. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].
Tan YX; Luo J; Huang JX; Luo DM; Liang HY; Zhou X; Liu XL; Xu N
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):323-329. PubMed ID: 35680632
[No Abstract] [Full Text] [Related]
26. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
Talpaz M; Erickson-Viitanen S; Hou K; Hamburg S; Baer MR
J Hematol Oncol; 2018 Aug; 11(1):101. PubMed ID: 30086777
[TBL] [Abstract][Full Text] [Related]
27. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
[TBL] [Abstract][Full Text] [Related]
28. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
[TBL] [Abstract][Full Text] [Related]
29. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
Wade R; Rose M; Neilson AR; Stirk L; Rodriguez-Lopez R; Bowen D; Craig D; Woolacott N
Pharmacoeconomics; 2013 Oct; 31(10):841-52. PubMed ID: 23996108
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Zhang Y; Zhou H; Duan M; Gao S; He G; Jing H; Li J; Ma L; Zhu H; Chang C; Du X; Hong M; Li X; Liu Q; Wang W; Xu N; Yang H; Lu B; Yin H; Wu L; Suo S; Zhao Q; Xiao Z; Jin J
Am J Hematol; 2023 Oct; 98(10):1588-1597. PubMed ID: 37470365
[TBL] [Abstract][Full Text] [Related]
31. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
32. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA; Vannucchi AM; Mead A; Egyed M; Szoke A; Suvorov A; Jakucs J; Perkins A; Prasad R; Mayer J; Demeter J; Ganly P; Singer JW; Zhou H; Dean JP; Te Boekhorst PA; Nangalia J; Kiladjian JJ; Harrison CN
Lancet Haematol; 2017 May; 4(5):e225-e236. PubMed ID: 28336242
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study.
Gupta V; Wolleschak D; Hasselbalch H; Vannucchi AM; Koschmieder S; Cervantes F; Li Y; Dong T; Wroclawska M; Bharathy S; Harrison C
Blood Adv; 2020 Jul; 4(13):3063-3071. PubMed ID: 32634234
[TBL] [Abstract][Full Text] [Related]
34. Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Passamonti F; Gupta V; Martino B; Foltz L; Zaritskey A; Al-Ali HK; Tavares R; Maffioli M; Raanani P; Giraldo P; Griesshammer M; Guglielmelli P; Bouard C; Paley C; Tiwari R; Vannucchi AM
Hematol Oncol; 2021 Oct; 39(4):558-566. PubMed ID: 34224180
[TBL] [Abstract][Full Text] [Related]
35. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
[TBL] [Abstract][Full Text] [Related]
36. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Passamonti F; Griesshammer M; Palandri F; Egyed M; Benevolo G; Devos T; Callum J; Vannucchi AM; Sivgin S; Bensasson C; Khan M; Mounedji N; Saydam G
Lancet Oncol; 2017 Jan; 18(1):88-99. PubMed ID: 27916398
[TBL] [Abstract][Full Text] [Related]
37. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Verstovsek S; Gotlib J; Mesa RA; Vannucchi AM; Kiladjian JJ; Cervantes F; Harrison CN; Paquette R; Sun W; Naim A; Langmuir P; Dong T; Gopalakrishna P; Gupta V
J Hematol Oncol; 2017 Sep; 10(1):156. PubMed ID: 28962635
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.
Bose P; Swaminathan M; Pemmaraju N; Ferrajoli A; Jabbour EJ; Daver NG; DiNardo CD; Alvarado Y; Yilmaz M; Huynh-Lu J; Qiao W; Wang X; Matamoros A; Zhou L; Pierce S; Schroeder KD; Kantarjian HM; Verstovsek S
Leuk Lymphoma; 2019 Jul; 60(7):1767-1774. PubMed ID: 30632841
[TBL] [Abstract][Full Text] [Related]
39. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
40. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM
Br J Haematol; 2013 May; 161(4):508-16. PubMed ID: 23480528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]